| 1. |
|
|
| 2. |
- Carlsson, Rose-Marie, et al.
(författare)
-
Control of pertussis--lessons learnt from a 10-year surveillance programme in Sweden.
- 2009
-
Ingår i: Vaccine. - : Elsevier BV. - 1873-2518 .- 0264-410X. ; 27:42, s. 5709-18
-
Tidskriftsartikel (refereegranskat)abstract
- Sweden was the only country in the world without any general pertussis vaccination when acellular pertussis (aP) vaccines were introduced. Since 1996 aP vaccines are given at the ages of 3, 5 and 12 months, with a 99% coverage, and until 2007 without a later booster. The long-term effects of aP vaccines, monitored within an enhanced surveillance project, were discussed at an international workshop in Stockholm in November 2008. The unique Swedish experience demonstrates that aP vaccines are capable of achieving the primary goal of a national vaccination programme, i.e., to significantly reduce the burden of pertussis in pre-school children. Throughout the 10-year surveillance period the highest age-specific incidence was reported in unvaccinated infants or those who had received only one dose, with most hospitalisations in this age group and eight deaths among unvaccinated infants. Complementary strategies are needed to achieve further reduction in morbidity from circulation of Bordetella pertussis.
|
|
| 3. |
- Carlsson, Rose-Marie, et al.
(författare)
-
[Time for booster doses against whooping cough for 10-year-old children]
- 2005
-
Ingår i: Lakartidningen. - 0023-7205. ; 102:35, s. 2394-8
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Acellular pertussis vaccine was introduced in Sweden in 1996 at the age of 3, 5 and 12 months, after a 17 year period without general vaccination against pertussis. At present, the incidence of notified pertussis has decreased to 1/10 of what was seen 10 years ago. In spite of the dramatic decrease, the disease is not eliminated. In accordance with the experience of other countries, most cases in Sweden are reported among older children and adults, while the highest risk of severe disease is still seen in infants. Many industrialized countries have introduced booster dose(s) in order to control the spread of pertussis. The Swedish National Board of Health and Welfare has recently initiated a major revision of the vaccines used and the schedule of the national vaccination program. Until the final proposal and in order not to miss the opportunity to boost pertussis immunity in children who were vaccinated as infants at the reintroduction of pertussis vaccination, the Board now recommends the Swedish municipalities as an interim measure to include pertussis in the current school booster against diphtheria and tetanus at 10 years of age with a full dose vaccine.
|
|
| 4. |
- Carlsson, Rose-Marie, et al.
(författare)
-
Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years
- 2015
-
Ingår i: Vaccine. - : Elsevier BV. - 0264-410X .- 1873-2518. ; 33:31, s. 3717-3725
-
Tidskriftsartikel (refereegranskat)abstract
- Prior study children from a DTaP efficacy trial were recruited at ages 5 and 15 years to randomized booster trials addressing immunogenicity and reactogenicity; 475 preschool children received mixed or separate injections of a reduced antigen vaccine (Tdap5, Sanofi Pasteur MSD) and an inactivated polio vaccine, and 230 adolescents received the same or another booster vaccine (Tdap1, SSI, Denmark). Pre-vaccination antibody concentrations against pertussis antigens were significantly higher at 15 than 5 years of age, probably due to natural boosting between the studies. Tdap5 induced comparable anti-PT concentrations at both ages, but antibody responses were significantly higher to filamentous haemagglutinin, pertactin and fimbriae 2/3 in adolescents. As expected, a higher amount of PT (Tdap1, 20 mu g) induced a stronger anti-PT response than a lower amount (Tdap5, 2.5 mu g). The frequency of adverse events was low and there were no serious adverse reactions. All local reactions had an early onset and a short duration. A large swelling or redness of more than half of the upper arm circumference was reported in 8/475 5-year-olds and in 6/230 15-year-olds. Children vaccinated with Tdap5 reported more moderate pain in adolescence than at preschool age, whereas itching was only reported in preschool children. Sweden introduced DTaP vaccines in 1996 after a 17-year hiatus with no general pertussis vaccination and pertussis was still endemic at the time of the studies. The frequency of adverse events was nevertheless low in both preschool children and adolescents and antibody responses were adequate. These studies document immunogenicity and reactogenicity in a trial cohort consecutively vaccinated with acellular pertussis vaccines from infancy to adolescence. (C) 2015 Elsevier Ltd. All rights reserved.
|
|
| 5. |
|
|
| 6. |
- Carlsson, Rose-Marie, et al.
(författare)
-
Vaccinscheman inom EU behöver göras mer lika : More equal vaccination schedules in the European Union needed
- 2008
-
Ingår i: Läkartidningen. - Stockholm : Sveriges läkarförbund. - 0023-7205 .- 1652-7518. ; 105:22, s. 1665-1669
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The worldwide variation in vaccination schedules often induces questions about complementary vaccinations to children in migrating families. Also the European vaccination programmes seem to differ widely, but there are in fact many similarities. A two or three-dose priming schedule, with 1, 1 ? or 2 months interval within the three-dose schedule, is used for immunisation against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b and in many countries also against hepatitis B. In some countries hepatitis B vaccination is started at birth. An early booster at 10-24 months is also generally implemented, with very few exceptions. At least one additional booster dose against diphtheria and tetanus is recommended within the age intervals 4-7 or 11-18 years of age. Most countries also have scheduled boosters against polio and pertussis within these intervals. Nowadays all countries offer two doses of MMR. The first dose is usually given at 12-18 months of age, while there is a wide age range for the second dose. A majority of countries give the second MMR at 3-9 years of age, five countries at 13-24 months whereas nine countries vaccinate at 9-13 years of age.
|
|
| 7. |
- Carlsson, Rose-Marie, et al.
(författare)
-
[Whooping cough is life-threatening for small children. Generous prophylaxis and contact tracing reduce the risks]
- 2005
-
Ingår i: Lakartidningen. - 0023-7205. ; 102:35, s. 2390-2
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The article presents clinical features of pertussis in older children and adults as well as in unvaccinated infants, with the aim to increase the awareness of the disease and to promote implementation of chemoprophylaxis in households with infants. The national routines for reporting according to the Communicable Diseases Act are outlined, contact-tracing around cases of pertussis being mandatory since July 2004.
|
|
| 8. |
|
|
| 9. |
- Hallingström, Maria, et al.
(författare)
-
The association between selected mid-trimester amniotic fluid candidate proteins and spontaneous preterm delivery
- 2020
-
Ingår i: Journal of Maternal-Fetal and Neonatal Medicine. - : Informa UK Limited. - 1476-7058 .- 1476-4954. ; 33:4, s. 583-592
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: The aim of this study was to explore inflammatory response and identify early potential biomarkers in mid-trimester amniotic fluid associated with subsequent spontaneous preterm delivery (PTD). Methods: A cohort study was performed at Sahlgrenska University Hospital/Östra, Gothenburg, Sweden, between 2008 and 2010. Amniotic fluid was collected from consecutive women undergoing mid-trimester transabdominal genetic amniocentesis at 14–19 gestational weeks. Clinical data and delivery outcome variables were obtained from medical records. The analysis included 19 women with spontaneous PTD and 118 women who delivered at term. A panel of 26 candidate proteins was analyzed using Luminex xMAP technology. Candidate protein concentrations were analyzed with ANCOVA and adjusted for plate effects. Results: The median gestational age at delivery was 35 + 3 weeks in women with spontaneous PTD and 40 + 0 weeks in women who delivered at term. Nominally significantly lower amniotic fluid levels of adiponectin (PTD: median 130,695 pg/mL (IQR 71,852–199,414) vs term: median 185,329 pg/mL (IQR (135,815–290,532)), granulocyte-macrophage colony stimulating factor (PTD: median 137 pg/mL (IQR 74–156) vs term: median 176 pg/mL (IQR 111–262)), and macrophage migration inhibitory factor (PTD: median 3025 pg/mL (IQR 1885–3891) vs term: median 3400 pg/mL (IQR 2181–5231)) were observed in the spontaneous PTD group, compared with the term delivery group, after adjusting for plate effects. No significant differences remained after Bonferroni correction for multiple comparisons. Conclusions: Our results are important in the process of determining the etiology behind spontaneous PTD but due to the non-significance after Bonferroni correction, the results should be interpreted with caution. Further analyses of larger sample size will be required to determine whether these results are cogent and to examine whether microbial invasion of the amniotic cavity or intra-amniotic inflammation occurs in asymptomatic women in the mid-trimester with subsequent spontaneous PTD.
|
|
| 10. |
- Nilsson, Lennart, et al.
(författare)
-
Bra immunsvar av vaccination mot difteri, stelkramp och kikhosta i årskurs 4 : Lokala reaktioner mycket vanliga – och förväntade
- 2009
-
Ingår i: Läkartidningen. - 0023-7205 .- 1652-7518. ; 106:38, s. 2357-2361
-
Tidskriftsartikel (refereegranskat)abstract
- Acellulärt kikhostevaccin, difterivaccin och stelkrampsvaccin gav bra serologiska svar vid påfyllnadsvaccination vid 10 års ålder. Även skolbarn som aldrig fått kikhostevaccin svarade med antikroppar mot kikhosta efter endast en dos acellulärt kikhostevaccin.Lokala biverkningar som ont i armen, rodnad/svullnad och klåda var mycket vanliga, och dessa lokalreaktioner höll i sig vanligtvis 3–4 dagar.Större lokala reaktioner om minst fem centimeters rodnad eller svullnad drabbade mellan vart tredje till vart sjätte barn.Dessa reaktioner är ofarliga, men det är viktigt att korrekt informera skolelever och föräldrar om vilka vanliga reaktioner som kan förväntas vid påfyllnadsvaccination mot difteri, stelkramp och kikhosta i denna ålder.
|
|
